Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …

Background Medication non-adherence can result in poor health outcomes. Understanding
differences in adherence rates to non-vitamin K oral anticoagulants (NOACs) could guide …

Background Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …

Background Dabigatran is one of the three newer oral anticoagulants (OACs) recently
approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) …

New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …

Study Objective Patients with nonvalvular atrial fibrillation (NVAF) often have multiple
comorbidities requiring concomitant medications in addition to their oral anticoagulant …

BACKGROUND: Adherence to oral anticoagulant (OAC) agents is important for patients with
nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …

Background Dabigatran, rivaroxaban, and apixaban have been approved for use in patients
with atrial fibrillation based upon randomized trials demonstrating their comparable or …